ROTHBLATT MARTINE A sold $5.3M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $558.87 ($553.12–$563.24, $5.31M total) across 10 trades on 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor for follow-on insider activity, but the presence of a 10b5-1 plan generally lowers the probability that this sale reflects new negative fundamentals.
Market read
A $5.31M CEO open-market sale is disclosed, but it is explicitly under a pre-arranged 10b5-1 plan, suggesting limited incremental information.
What to watch
The filing does not indicate why the sale occurred; without accompanying operational or guidance news, trading impact should be treated as sentiment-only.
Background
The filing is an SEC Form 4 insider transaction by UTHR’s chairperson and CEO, using an open-market sale code S under a pre-arranged 10b5-1 plan.
Ticker impact
SEC Form 4 shows UTHR CEO and chair Martine Rothblatt sold 9,500 shares in open-market transactions totaling about $5.31M.
Likely limited, short-lived sentiment impact; any move would be small unless accompanied by other company-specific catalysts.
The article is a primary-source insider transaction disclosure with a stated 10b5-1 plan, which typically reduces the signal strength versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
10b5-1 sales are often routine liquidity events, so the market may largely ignore the signal.
Key entities
- issuerUNITED THERAPEUTICS Corp
Company whose CEO/chairperson filed the Form 4 insider sale disclosure.
- insiderROTHBLATT MARTINE A
Chairperson and CEO who sold 9,500 shares across 10 trades on 2026-07-07.
